Archive · 30 Jun 2025
Marksans Pharma Shares Surge After USFDA Approval
Marksans Pharma's stock went up because a company they own got a good report from the US government.
The US government checked their New York factory from April 16 to 24, 2025.
The company got a report that said everything was okay.
Because of this good news, the company's stock price went up.
Also, the company's profits went up, meaning they made more money.
Marksans Pharma shares rose 4.5% after its subsidiary received an EIR from the USFDA.
Time-Cap Laboratories, a Marksans Pharma subsidiary, received the Establishment Inspection Report.
The USFDA inspected the New York facility from April 16-24, 2025.
The subsidiary received one inspectional observation in Form 483.
The company's net profit increased by 15.6% in the fourth quarter of the financial year 2025.
- Who
- Marksans Pharma and its subsidiary Time-Cap Laboratories.
- What
- Marksans Pharma shares gained after its subsidiary received an EIR from the USFDA.
- When
- Shares gained on June 30th, after an inspection in April 2025.
- Where
- New York manufacturing facility.
- Why
- Due to the positive outcome of the USFDA inspection.
- Stock Gain
- 4.5%
- Subsidiary
- Time-Cap Laboratories
- Inspection Dates
- April 16-24, 2025
- Observation
- One inspectional observation in Form 483
- Q4 FY2025 Net Profit Increase
- 15.6%